论文部分内容阅读
本研究探讨骨髓增生异常综合征(MDS)和急性白血病(AL)病人血清血小板生成素(TPO)和乳酸脱氢酶(LDH)的含量及其临床意义。采用双抗体夹心酶联免疫吸附法,测定了25例MDS、40例急性白血病病人化疗前、骨髓抑制期及骨髓恢复期血清中TPO含量;同时用速率法(由L到P)测定上述病人血清乳酸脱氢酶水平,并以15例健康体检者上述指标作为正常对照。结果发现,ALL、AML和MDS病人治疗前血清中TPO、LDH水平均明显高于正常对照组,差异有显著性意义(q=7.2943-27.4149,p<0.001),骨髓抑制期及恢复期患者血清TPO、LDH水平比治疗前明显降低(q=7.2943-25.9396,p<0.001),与正常对照组比较无显著性差异(q=1.4816-2.5657,p>0.05)。结论:血清TPO、LDH水平与恶性血液病患者疾病恶性程度密切相关,检测患者血清TPO、LDH水平可用于恶性血液病的疗效观测。
This study was to investigate the clinical significance of serum platelet-thrombopoietin (TPO) and lactate dehydrogenase (LDH) in patients with myelodysplastic syndrome (MDS) and acute leukemia (AL). The serum TPO levels of 25 patients with MDS and 40 patients with acute leukemia before chemotherapy, in myelosuppression and in bone marrow recovery were determined by double antibody sandwich enzyme-linked immunosorbent assay (ELISA). Meanwhile, the serum levels of these patients were determined by the rate method (L to P) Lactate dehydrogenase levels, and 15 healthy subjects were used as a normal control. The results showed that the serum levels of TPO and LDH in ALL, AML and MDS patients before treatment were significantly higher than those in normal control group (q = 7.2943-27.4149, p <0.001), and the serum levels of myelosuppression and convalescent patients TPO, LDH levels were significantly lower than those before treatment (q = 7.2943-25.9396, p <0.001), and no significant difference compared with the normal control group (q = 1.4816-2.5657, p> 0.05). Conclusion: The levels of serum TPO and LDH are closely related to the degree of malignant disease in patients with hematologic malignancies. The serum levels of TPO and LDH can be used to observe the curative effect of hematologic malignancies.